STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering
STRATA Skin Sciences (NASDAQ:SSKN), a medical technology company focused on dermatologic treatments, has completed its previously announced registered direct offering. The company successfully issued 1,097,547 shares of common stock at $2.204 per share, raising gross proceeds of approximately $2.42 million.
The offering, which closed on September 4, 2025, was conducted through Ladenburg Thalmann & Co. Inc. as the exclusive placement agent. STRATA plans to utilize the net proceeds for working capital and general corporate purposes. The securities were offered under an effective S-3 shelf registration statement.
STRATA Skin Sciences (NASDAQ:SSKN), azienda di tecnologia medica specializzata in trattamenti dermatologici, ha completato l'offerta diretta registrata precedentemente annunciata. La società ha emesso con successo 1.097.547 azioni ordinarie al prezzo di $2,204 per azione, raccogliendo proventi lordi per circa $2,42 milioni.
L'offerta, chiusa il 4 settembre 2025, è stata gestita in esclusiva da Ladenburg Thalmann & Co. Inc. come agente di collocamento. STRATA intende utilizzare i proventi netti per il capitale circolante e finalità aziendali generali. I titoli sono stati offerti ai sensi di un prospetto S-3 già efficace.
STRATA Skin Sciences (NASDAQ:SSKN), una empresa de tecnología médica centrada en tratamientos dermatológicos, ha completado la oferta directa registrada anunciada anteriormente. La compañía emitió con éxito 1.097.547 acciones ordinarias a $2,204 por acción, recaudando ingresos brutos por aproximadamente $2,42 millones.
La oferta, que se cerró el 4 de septiembre de 2025, se realizó a través de Ladenburg Thalmann & Co. Inc. como agente colocador exclusivo. STRATA pretende utilizar los ingresos netos para capital de trabajo y fines corporativos generales. Los valores se ofrecieron bajo una declaración de registro S-3 vigente.
STRATA Skin Sciences (NASDAQ:SSKN)는 피부과 치료에 중점을 둔 의료기술 회사로, 이전에 발표한 등록 직접 공모를 완료했습니다. 회사는 보통주 1,097,547주를 주당 $2.204에 성공적으로 발행하여 약 $2.42백만의 총수익을 조달했습니다.
이번 공모는 2025년 9월 4일에 마감되었으며 독점 배정대리인으로 Ladenburg Thalmann & Co. Inc.가 참여했습니다. STRATA는 순수익을 운전자본 및 일반 기업 목적에 사용할 계획입니다. 해당 증권은 유효한 S-3 선반 등록명세서에 따라 제공되었습니다.
STRATA Skin Sciences (NASDAQ:SSKN), une société de technologie médicale spécialisée dans les traitements dermatologiques, a finalisé son offre directe enregistrée précédemment annoncée. La société a émis avec succès 1 097 547 actions ordinaires au prix de 2,204 $ par action, levant des produits bruts d'environ 2,42 millions de $.
L'offre, qui s'est clôturée le 4 septembre 2025, a été réalisée par Ladenburg Thalmann & Co. Inc. en tant qu'agent de placement exclusif. STRATA prévoit d'utiliser le produit net pour le fonds de roulement et des besoins généraux de l'entreprise. Les titres ont été offerts en vertu d'une déclaration d'enregistrement S-3 effective.
STRATA Skin Sciences (NASDAQ:SSKN), ein Medizintechnikunternehmen mit Schwerpunkt auf dermatologischen Behandlungen, hat sein zuvor angekündigtes registriertes Direktangebot abgeschlossen. Das Unternehmen hat erfolgreich 1.097.547 Stammaktien zu $2,204 pro Aktie ausgegeben und dadurch Bruttoerlöse von etwa $2,42 Millionen erzielt.
Das Angebot, das am 4. September 2025 abgeschlossen wurde, erfolgte über Ladenburg Thalmann & Co. Inc. als exklusivem Platzierungsagenten. STRATA plant, die Nettoerlöse für das Betriebskapital und allgemeine Unternehmenszwecke zu verwenden. Die Wertpapiere wurden unter einer wirksamen S-3-Prospektregistrierung angeboten.
- Secured $2.42 million in additional funding
- Strengthened working capital position
- Potential dilution for existing shareholders due to issuance of 1,097,547 new shares
HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the closing of its previously announced registered direct offering for the issuance and sale of 1,097,547 shares of the Company’s common stock at a per share purchase price of
Ladenburg Thalmann & Co. Inc. acted as exclusive placement agent for the offering.
The closing of the registered direct offering occurred on September 4, 2025. The gross proceeds of the offering, before deducting the placement agent fees and other offering expenses payable by the Company, were approximately
The securities described above were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-283418), declared effective by the Securities and Exchange Commission (“SEC”) on December 18, 2024. The offering was made only by means of a prospectus supplement filed with the SEC on September 3, 2025, which forms a part of the effective registration statement. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC’s website at http://www.sec.gov or by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice. For more information, please visit www.strataskinsciences.com.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions, labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
FAQ
How much did STRATA Skin Sciences (SSKN) raise in their September 2025 offering?
What is the price per share for STRATA Skin Sciences' September 2025 offering?
How many shares did STRATA Skin Sciences (SSKN) issue in the September 2025 offering?
How will STRATA Skin Sciences use the proceeds from the September 2025 offering?
Who was the placement agent for STRATA Skin Sciences' September 2025 offering?
